Industry Verticals »

All Categories

Insights »

About TMR »

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market (Biomarker Type: Serum Biomarkers, Biomarker Panels, Fibrosis Biomarkers, Imaging Biomarkers, and Others; and End User: Hospitals, Diagnostic Centers, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

High Demand for Non-invasive NASH Treatment to Augment Market

Over the past couple of decades, the number of obesity, diabetes, and non-alcoholic fatty liver diseases (NAFLD) cases have increased at a rapid pace. The range of NAFLD extends from steatosis to non-alcoholic steatohepatitis (NASH). The rise in the prevalence of NAFLD has caused a great amount of economic burden on nations worldwide and as per trends, patients suffering from NAFLD-related diseases have emerged as one of the major subset of people requiring liver transplant. One of the major factors that is likely to propel the adoption of NASH biomarker is the high prevalence of NAFLD and the undesirable outcomes. The adoption of conventional techniques to address NAFLD such as biopsy is steadily declining due to limitations, including sampling bias, complications such as pain, bleeding, mortality, and poor acceptability.

The demand for non-invasive techniques to treat NAFLD has witnessed a consistent growth over the past decade. Non-invasive techniques that have gained significant popularity to combat NAFLD include NASH, NAFLD-based fibrosis, and steatosis, among others. The surge in demand for these non-invasive techniques is expected to boost the demand for NASH biomarkers during the forecast period. In recent times, players operating in the global NASH biomarkers are increasingly investigating the algorithms that consist non-imaging and imaging biomarkers to diagnose fibrosis and minimize biopsies in clinical settings. Technological advancements, research and development activities coupled with high prevalence of NAFLD are some of major factors that are likely to drive the expansion of the non-alcoholic steatohepatitis (NASH) biomarkers market during the assessment period. At the back of these factors, the global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to attain a market value of ~US$ 2 Bn by the end of 2027.

non alcoholic steatohepatitis biomarkers market Infographic

Adoption of NASH Biomarkers to Address Idiopathic Pulmonary Fibrosis

Advancements in the healthcare sector, along with research activities are likely to play a key role in the growth of the global non-alcoholic steatohepatitis (NASH) biomarkers market. In recent times, a considerable amount of research has been undertaken in discovering the potential treatments for idiopathic pulmonary fibrosis (IPF). In the past decade, the progression from NAFLD to NASH has increased at a rapid pace and has emerged as one of the most prevalent chronic liver conditions particularly in the Western regions, including North America and Europe– a factor due to which the production of NASH biomarkers is set to witness a considerable growth.

At present, while researchers are increasingly focusing on improving the efficacy of NASH biomarkers, healthcare providers, medical professionals, and healthcare workers are projected to increase awareness regarding NASH. Medical experts are of the opinion that the prevalence of NASH is set to grow at a rapid pace in the coming decade due to which, robust measures are required to combat the same. Public health groups, along with government organizations particularly in developed regions are focusing on formulating new guidelines that govern the management of NASH. Innovations within the non-alcoholic steatohepatitis (NASH) biomarkers market are primarily targeting improvements in non-invasive screening and diagnostic testing. In addition, companies operating in the current market landscape are increasingly focusing on different molecules for the treatment of NASH. Moreover, at present, while a large number of drugs are in phase three trials, multiple drugs are in the pipeline across world. Companies operating in the current market landscape are primarily focusing on replacing painful and invasive biopsies with non-invasive NASH biomarkers. The launch of the new project by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium aimed toward standardizing biological markers to improve the diagnosis of NASH. The Non-Invasive Biomarkers of Metabolic Liver Disease project is expected to make a direct comparison between conventional and non-conventional techniques to address NASH and suggest the best tools to diagnose NASH. Such projects are expected to promote the sales of NASH biomarkers during the forecast period and thus, will augment the growth of the non-alcoholic steatohepatitis (NASH) biomarkers market.

Companies Adapt, Adjust, and Assess Pipeline Products, Seek FDA Approval

The advent of the novel coronavirus pandemic is expected to create major roadblocks for companies operating in the current non-alcoholic steatohepatitis (NASH) biomarkers market. Mobilization of researchers, front-line clinicians, manufacturers, and other participants in the value chain has emerged as a major area of concern amidst the chaos. On the heels of the health and economic crisis worldwide, The Global Liver Institute, recently revealed its plans to address the global pandemic by adapting and provide creative solutions. While supply chains within the non-alcoholic steatohepatitis (NASH) biomarkers market are likely to be disrupted, companies should focus on formulating effective business continuity strategies and focus on product diversification to address the business challenges put forward by the global pandemic.

non alcoholic steatohepatitis biomarkers market segmentation

Analysts’ Viewpoint

The global non-alcoholic steatohepatitis (NASH) biomarkers market is expected to grow at a staggering CAGR of ~21% during the forecast period. The market growth can be attributed to a host of factors, including high demand for non-invasive techniques to address NASH, research and development activities, government support for the development of NASH biomarkers, and high focus on curbing the prevalence of diabetes and NAFLD. Market players are anticipated to focus on the development of new NASH biomarkers and attain the approval from the FDA. Moreover, North America and Europe are likely to be the hotbeds of development within the global non-alcoholic steatohepatitis (NASH) biomarkers market.  

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Overview

  • The global non-alcoholic steatohepatitis (NASH) biomarkers market was valued at ~US$ 300 Mn in 2018 and is projected to expand at a rapid pace from 2019 to 2027. Rise in NAFLD and NASH conditions; increase in patient pool suffering from obesity and metabolic diseases; rise in geriatric population; growth in Type 2 diabetes and pre-diabetes in adult patients; surge in demand for non-invasive diagnostic techniques; and increase in awareness about NASH condition and innovative diagnosis tools, especially in developing markets, are anticipated to propel the global non-alcoholic steatohepatitis (NASH) biomarkers market. 
  • NASH, also known as non-alcoholic steatohepatitis, is a progressive form of non alcoholic fatty liver disease (NAFLD). NAFLD is a condition in which fat is accumulated in the liver and the continuous fat deposition may cause liver inflammation and liver cell damage. This is termed as NASH condition. Increase in worldwide prevalence of obesity, type 2 diabetes, pre-diabetes, and metabolic diseases are major reasons for increase in prevalence of non-alcoholic steatohepatitis condition. Thus, innovative diagnostic tools are introduced in the market to accurately diagnose the non-alcoholic steatohepatitis condition. Liver biopsy is one of the standard tools for diagnosis of NASH condition. However, due to high cost of this procedure, many companies have introduced biomarkers as a diagnostic tool for NASH patients. Various non-invasive biomarkers are available for detection of the NASH condition, including serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, gene biomarkers, oxidative stress biomarkers, and Cytokeratin-18.
  • As per research, worldwide prevalence of NASH is estimated to be in a range of 1.5%–6.45%, respectively, in 2019. NASH prevalence across globe is expected to grow by 63% by 2030. Several pharmaceutical and biotechnology companies are investing in development of therapeutics for NASH. Currently, 95 drug candidates from different players are in pipeline ranging from preclinical to phase 3 trials. These players would require NASH biomarker diagnostics to monitor and evaluate drug effectiveness during clinical trials. Various companies have entered into collaboration to further strengthen and develop biomarkers, thereby augmenting the NASH biomarkers market in the near future.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Segmentation

  • The global non-alcoholic steatohepatitis (NASH) biomarkers market has been segmented based on biomarker type, end user, and region
  • In terms of biomarker, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been classified into serum biomarkers, biomarker panels, fibrosis biomarkers, imaging biomarkers, and others. The serum biomarkers segment is further classified into cytokeratin-18 (CK 18) marker, inflammatory markers, and others. The serum biomarkers segment held a largest market share, owing to availability of various tests in the market. The segment also has higher accuracy in differentiating NASH indications. Cell apoptosis increases during the progression of NASH. Markers such as fragments of cytokeratin-18 and ferritin are measured and found to be promising markers of NASH. CK-18 is considered as the popular and potential biomarker for detecting NASH indication. The others segment includes gene biomarkers and oxidative stress biomarkers which offer promising results in terms of higher accuracy and are considered to be inexpensive and simple non-invasive techniques.
  • In terms of end user, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been segregated into hospitals, diagnostic centers, and others. The diagnostic centers segment dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, owing to increase in awareness about the NASH indication for early diagnosis followed by its effective treatment. Availability of technically advanced tools such as biomarkers tests in diagnostic centers coupled with presence of expertise is likely to drive the diagnostic centers segment.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Regional Segmentation

  • In terms of region, the global non-alcoholic steatohepatitis (NASH) biomarkers market has been split into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
  • North America dominated the global non-alcoholic steatohepatitis (NASH) biomarkers market in 2018, owing to rise in prevalence of NASH associated conditions such as obesity and type 2 diabetes in the region. Several market players such as Quest Diagnostics for Hepascore and Exalenz Biosciences Ltd. are opting to enter North America through collaborations and alliances. Demand for non-invasive diagnostic tests for NASH and related diseases is high due to accuracy and operational limitations and associated hazards of liver biopsy. Rise in adoption of minimal invasive surgeries, growing geriatric population, and investments by key players in R&D to develop innovative and promising biomarkers are estimated to boost the non-alcoholic steatohepatitis (NASH) biomarkers market in the region.
  • The non-alcoholic steatohepatitis (NASH) biomarkers market in Latin America and Middle East & Africa is anticipated to expand at a faster pace than other regions during the forecast period. Rising patient population suffering from NASH condition is a major factor likely to propel the market in Latin America and the Middle East. Latin America likely to exhibit highest CAGR, owing to prevalence of NASH condition. For instance, in Brazil, the prevalence rate of NASH condition is 35.2%, in Chile, it is 23%, in Mexico, it is around 17%, and in Columbia it is around 26.6%. As per NCBI, the prevalence of NASH indication in Middle East & Africa is estimated to reach more than 12,534,000 cases in Saudi Arabia and 372,000 cases in the UAE by 2030. All these statistics are likely to boost the NASH biomarkers market in the region.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market: Major Players

  • Key players operating in the global non-alcoholic steatohepatitis (NASH) biomarkers market include 
    • Biopredictive
    • Quest Diagnostics
    • Exalenz Bioscience Ltd
    • GENFIT
    • Siemens Healthineers
    • ONE WAY LIVER
    • S.L
    • Prometheus Laboratories Inc
    • Gilead Sciences Ltd.
  • These players are focused on adopting organic and inorganic growth strategies to strengthen product portfolio and expand their alliances with other companies. Key players have adopted strategies such as investment into research & development of efficient non-invasive biomarkers, creating awareness about non-alcoholic steatohepatitis indication, expansion of geographic footprint, and collaborations & acquisitions, in order to be competitive in the global non-alcoholic steatohepatitis (NASH) biomarkers market.

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market - Segmentation

Biomarker Type

Serum Biomarkers

  • Cytokeratin-18 (CK 18)-Biomarker
  • Inflammatory Markers
  • Others

Biomarker Panels

Fibrosis Biomarkers

Imaging Biomarkers

Others

End User

Hospitals

Diagnostic Centers

Others

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of non-alcoholic steatohepatitis biomarkers market?

Non-alcoholic steatohepatitis biomarkers market to reach valuation of value of ~US$ 2 Bn by the end of 2027

What is the anticipated CAGR of the non-alcoholic steatohepatitis biomarkers market in the forecast period?

Non-alcoholic steatohepatitis biomarkers market is expected to grow at a staggering CAGR of ~21% during 2019 - 2027

What are the key driving factors for the growth of the non-alcoholic steatohepatitis biomarkers market?

Non-alcoholic steatohepatitis biomarkers market is driven by the increase in prevalence of NAFLD & NASH disease

Which region is expected to project the highest market share in the global non-alcoholic steatohepatitis biomarkers market?

North America accounted for a major share of the global non-alcoholic steatohepatitis biomarkers market

Who are the key players in the non-alcoholic steatohepatitis biomarkers market?

Key players in the global non-alcoholic steatohepatitis biomarkers market include Biopredictive, Quest Diagnostics, Exalenz Bioscience Ltd, GENFIT, Siemens Healthineers

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Non-alcoholic Steatohepatitis Biomarkers Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Disease Prevalence & Incidence Rate globally with Key countries

        5.2. Regulatory Scenario by Region/globally 

        5.3. Pipeline Analysis 

    6. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by Biomarker Type  

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

            6.3.1. Serum Biomarkers 

                6.3.1.1. Cytokeratin-18 (CK 18) Marker

                6.3.1.2. Inflammatory markers

                6.3.1.3. Others 

            6.3.2. Biomarker Panel  

            6.3.3. Fibrosis Biomarkers

            6.3.4. Imaging Biomarkers 

            6.3.5. Others

        6.4. Market Attractiveness Analysis, by Biomarker Type  

    7. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by End-user 

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

            7.3.1. Hospitals 

            7.3.2. Diagnostic Centers

            7.3.3. Others

        7.4. Market Attractiveness Analysis, by End-user

    8. Global Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast, by Region 

        8.1. Key Findings

        8.2. Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe 

            8.2.3. Asia Pacific

            8.2.4. Latin America 

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness Analysis, by Region

    9. North America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

        9.1.  Introduction

            9.1.1.  Key Findings

        9.2.  North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

            9.2.1. Serum Biomarkers 

                9.2.1.1. Cytokeratin-18 (CK 18) Marker

                9.2.1.2. Inflammatory Markers

                9.2.1.3. Others 

            9.2.2. Biomarker Panel  

            9.2.3. Fibrosis Biomarkers

            9.2.4. Imaging Biomarkers 

            9.2.5. Others 

        9.3. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

            9.3.1. Hospitals

            9.3.2. Diagnostic Centers

            9.3.3. Others

        9.4. North America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country, 2017–2027

            9.4.1. U.S.

            9.4.2. Canada

        9.5. North America Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

            9.5.1. By Biomarker Type  

            9.5.2. By End-user 

            9.5.3. By Country

    10. Europe Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

        10.1.  Introduction

            10.1.1.  Key Findings

        10.2. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

            10.2.1. Serum Biomarkers 

                10.2.1.1. Cytokeratin-18 (CK 18) Marker

                10.2.1.2. Inflammatory Markers

                10.2.1.3. Others 

            10.2.2. Biomarker Panel  

            10.2.3. Fibrosis Biomarkers

            10.2.4. Imaging Biomarkers 

            10.2.5. Others 

        10.3. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

            10.3.1. Hospitals

            10.3.2. Diagnostic Centers

            10.3.3. Others

        10.4. Europe Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Spain

            10.4.5. Italy

            10.4.6. Rest of Europe

        10.5. Europe Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

            10.5.1. By Biomarker Type  

            10.5.2. By End-user 

            10.5.3. By Country/Sub-region

    11. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

        11.1.  Introduction

            11.1.1.  Key Findings

        11.2.  Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

            11.2.1. Serum Biomarkers 

                11.2.1.1. Cytokeratin-18 (CK 18) Marker

                11.2.1.2. Inflammatory Markers

                11.2.1.3. Others 

            11.2.2. Biomarker Panel  

            11.2.3. Fibrosis Biomarkers

            11.2.4. Imaging Biomarkers 

            11.2.5. Others 

        11.3. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

            11.3.1. Hospitals 

            11.3.2. Diagnostic Centers

            11.3.3. Others

        11.4. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Asia Pacific Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

            11.5.1. By Biomarker Type  

            11.5.2. By End-user 

            11.5.3. By Country/Sub-region

    12. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

        12.1.  Introduction

            12.1.1.  Key Findings

        12.2.  Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

            12.2.1. Serum Biomarkers 

                12.2.1.1. Cytokeratin-18 (CK 18) Marker

                12.2.1.2. Inflammatory Markers

                12.2.1.3. Others 

            12.2.2. Biomarker Panel  

            12.2.3. Fibrosis Biomarkers

            12.2.4. Imaging Biomarkers 

            12.2.5. Others 

        12.3. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

            12.3.1. Hospitals

            12.3.2. Diagnostic Centers

            12.3.3. Others  

        12.4. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Latin America Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

            12.5.1. By Biomarker Type  

            12.5.2. By End-user 

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Analysis and Forecast

        13.1.  Introduction

            13.1.1.  Key Findings

        13.2.  Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Biomarker Type, 2017–2027

            13.2.1. Serum Biomarkers 

                13.2.1.1. Cytokeratin-18 (CK 18) Marker

                13.2.1.2. Inflammatory Markers

                13.2.1.3. Others 

            13.2.2. Biomarker Panel  

            13.2.3. Fibrosis Biomarkers

            13.2.4. Imaging Biomarkers 

            13.2.5. Others 

        13.3. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by End-user, 2017–2027

            13.3.1. Hospitals

            13.3.2. Diagnostics Centers 

            13.3.3. Others 

        13.4. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Value Forecast, by Country/Sub-region, 2017–2027

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Middle East & Africa Non-alcoholic Steatohepatitis Biomarkers Market Attractiveness Analysis

            13.5.1. By Biomarker Type  

            13.5.2. By End-user 

            13.5.3. By Country/Sub-region

    14. Competitive Landscape

        14.1.  Market Share Analysis, by Company, 2018

        14.2.  Company Profiles

            14.2.1. Biopredictive 

                14.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.1.2. Product Portfolio

                14.2.1.3. Strategic Overview

                14.2.1.4. SWOT Analysis

            14.2.2. Quest Diagnostics

                14.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.2.2. Financial Overview

                14.2.2.3. Product Portfolio

                14.2.2.4. Strategic Overview

                14.2.2.5. SWOT Analysis

            14.2.3. Exalenz Bioscience Ltd 

                14.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.3.2. Financial Overview

                14.2.3.3. Product Portfolio

                14.2.3.4. Strategic Overview

                14.2.3.5. SWOT Analysis

            14.2.4. GENFIT

                14.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.4.2. Financial Overview

                14.2.4.3. Product Portfolio

                14.2.4.4. Strategic Overview

                14.2.4.5. SWOT Analysis

            14.2.5. Siemens Healthineers

                14.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.5.2. Financial Overview

                14.2.5.3. Product Portfolio

                14.2.5.4. Strategic Overview

                14.2.5.5. SWOT Analysis

            14.2.6.  ONE WAY LIVER, S.L

                14.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.6.2. Product Portfolio

                14.2.6.3. Strategic Overview

                14.2.6.4. SWOT Analysis

            14.2.7.  Prometheus Laboratories Inc.

                14.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.7.2. Product Portfolio

                14.2.7.3. Strategic Overview

                14.2.7.4. SWOT Analysis

            14.2.8. Gilead Sciences Ltd.

                14.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.2.8.2. Financial Overview

                14.2.8.3. Product Portfolio

                14.2.8.4. Strategic Overview

                14.2.8.5. SWOT Analysis

    List of Tables

    Table 01: Opportunity Map, by Biomarker Type, 2018

    Table 03: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Biomarker Type, 2017–2027

    Table 04: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

    Table 05: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 06: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast, by Region, 2017–2027

    Table 07: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

    Table 08: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

    Table 09: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 10: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2027

    Table 11: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

    Table 12: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

    Table 13: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 14: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 15: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

    Table 16: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

    Table 17: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 18: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 19: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

    Table 20: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

    Table 21: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 22: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    Table 23: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Biomarker Type, 2017–2027

    Table 24: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Serum Biomarker Type, 2017–2027

    Table 25: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by End-user, 2017–2027

    Table 26: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

    List of Figures

    Figure 01: Global Non-alcoholic Steatohepatitis Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027

    Figure 02: Market Share Analysis, by Region, 2018

    Figure 03: Global Non-alcoholic Steatohepatitis Biomarker Market Revenue Projection (US$ Mn), 2017–2027

    Figure 04 : Market Value Share, by Biomarker Type, 2018

    Figure 05: Market Value Share, by End-user, 2018

    Figure 06: Market Value Share, by Region, 2018

    Figure 07: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

    Figure 08: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

    Figure 09: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Serum Biomarkers, 2017–2027

    Figure 10: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Biomarker Panel, 2017–2027

    Figure 11: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Fibrosis Biomarkers, 2017–2027

    Figure 12: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Imaging Biomarkers , 2017–2027

    Figure 13: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2017–2027

    Figure 14: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

    Figure 15: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

    Figure 16: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2019–2027

    Figure 17: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Diagnostic Centers, 2019–2027

    Figure 18: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2019–2027

    Figure 19: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Region, 2018 and 2027

    Figure 20: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Region, 2019–2027

    Figure 21: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

    Figure 22: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

    Figure 23: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

    Figure 24: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

    Figure 25: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

    Figure 26: North America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country, 2018 and 2027

    Figure 27: North America Non-alcoholic Steatohepatitis ( NASH) Biomarkers Market Attractiveness, by Country, 2019–2027

    Figure 28: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

    Figure 29: Europe Non-alcoholic Steatohepatitis ( NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

    Figure 30: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

    Figure 31: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

    Figure 32: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

    Figure 33: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 34: Europe Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 35: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

    Figure 36: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

    Figure 37: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

    Figure 38: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

    Figure 39: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

    Figure 40: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 41: Asia Pacific Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 42: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

    Figure 43: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

    Figure 44: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

    Figure 45: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

    Figure 46: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

    Figure 47: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 48: Latin America Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 49: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2019–2027

    Figure 50: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Biomarker Type, 2018 and 2027

    Figure 51: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Biomarker Type, 2019–2027

    Figure 52: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by End-user, 2018 and 2027

    Figure 53: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by End-user, 2019–2027

    Figure 54: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Value Share, by Country/Sub-region, 2018 and 2027

    Figure 55: Middle East & Africa Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Attractiveness, by Country/Sub-region, 2019–2027

    Figure 56: Global Non-alcoholic Steatohepatitis (NASH) Biomarkers Market Position Analysis, by Company (2018)

    Figure 57: Quest Diagnostics, Research & Development (US$ Mn), 2016–2018

    Figure 58: Quest Diagnostics, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 59: Quest Diagnostics, Breakdown of Net Sales, by Business Segment, 2018

    Figure 60: Exalenz Bioscience Ltd , Breakdown of Net Sales, by Region, 2018

    Figure 61: Exalenz Bioscience Ltd , Research & Development (US$ Mn), 2016–2018

    Figure 62: Exalenz Bioscience Ltd , Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 63: Exalenz Bioscience Ltd , Breakdown of Net Sales, by Business Segment, 2018

    Figure 64: GENFIT, Breakdown of Net Sales, by Region, 2018

    Figure 65: GENFIT, Research & Development (US$ Mn), 2016–2018

    Figure 66: GENFIT, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 67: GENFIT, Breakdown of Net Sales, by Business Segment, 2018

    Figure 68: Siemens Healthineers, Breakdown of Net Sales, by Region, 2018

    Figure 69: Siemens Healthineers, Research & Development (US$ Mn), 2016–2018

    Figure 70: Siemens Healthineers, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 71: Siemens Healthineers, Breakdown of Net Sales, by Business Segment, 2018

    Figure 72: Gilead Sciences, Inc., Breakdown of Net Sales, by Region, 2018

    Figure 73: Gilead Sciences, Inc., Research & Development (US$ Mn), 2016–2018

    Figure 74: Gilead Sciences, Inc., Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 75: Gilead Sciences, Inc., Breakdown of Net Sales, by Business Segment, 2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Non-alcoholic Steatohepatitis (NASH) Biomarkers Market

Schedule a Call